Although evidence suggests that 5-HT(2A) and muscarinic M1/M4 receptors are implicated in the pathology of schizophrenia, the results are not conclusive. In the present study we tested the hypothesis that binding of 5-HT(2A) and M1/M4 receptors is altered in the postmortem brain of schizophrenia subjects. Quantitative autoradiography was employed to measure [(3)H]ketanserin binding to 5-HT(2A) receptors and [(3)H]pirenzepine binding to both M1 and M4 receptors in Brodmann's area 9 (BA9), caudate/putamen, and the hippocampal formation from six schizophrenic and six control subjects. A significant reduction in the density of 5HT(2A) receptors in BA 9 of schizophrenic subjects was observed (p=0.036). No significant difference was observed in the density of 5HT(2A) receptors in the hippocampus or caudate/putamen between the two groups. No significant changes in the density of M1/M4 receptors was observed in these three regions between the two groups. These findings support a possible involvement of the serotonergic system in the pathology of schizophrenia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.neulet.2004.12.059 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.
JAMA Psychiatry
August 2024
Karuna Therapeutics, Boston, Massachusetts.
Article Synopsis
- There is a critical demand for new antipsychotic medications that are more effective and have fewer side effects; xanomeline, a new muscarinic receptor agonist, shows promise in this area, especially when paired with trospium chloride to minimize side effects.
- The EMERGENT-3 trial tested xanomeline-trospium against a placebo in adults with schizophrenia experiencing acute psychosis, taking place at multiple sites in the US and Ukraine from April to December 2022.
- The study aimed to measure changes in psychiatric symptoms using the Positive and Negative Syndrome Scale (PANSS) and assess safety, with results expected to contribute to new treatment options for schizophrenia.
Beyond dopamine: Novel strategies for schizophrenia treatment.
Med Res Rev
September 2024
Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland.
Despite extensive research efforts aimed at discovering novel antipsychotic compounds, a satisfactory pharmacological strategy for schizophrenia treatment remains elusive. All the currently available drugs act by modulating dopaminergic neurotransmission, leading to insufficient management of the negative and cognitive symptoms of the disorder. Due to these challenges, several attempts have been made to design agents with innovative, non-dopaminergic mechanisms of action.
View Article and Find Full Text PDFM/M receptors as potential therapeutic treatments for schizophrenia: A comprehensive study.
Bioorg Med Chem
May 2024
School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, PR China.. Electronic address:
Muscarinic acetylcholine receptors (mAChRs) play a significant role in the pathophysiology of schizophrenia. Although activating mAChRs holds potential in addressing the full range of schizophrenia symptoms, clinical application of many non-selective mAChR agonists in cognitive deficits, positive and negative symptoms is hindered by peripheral side effects (gastrointestinal disturbances and cardiovascular effects) and dosage restrictions. Ligands binding to the allosteric sites of mAChRs, particularly the M1 and M4 subtypes, demonstrate activity in improving cognitive function and amelioration of positive and negative symptoms associated with schizophrenia, enhancing our understanding of schizophrenia.
View Article and Find Full Text PDFVirtual Screening, Docking, and Designing of New VEGF Inhibitors as Anti-cancer Agents.
Curr Drug Discov Technol
April 2024
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara, Gujarat, India.
Background: VEGFR-2 tyrosine kinase inhibitors are receiving a lot of attention as prospective anticancer medications in the current drug discovery process.
Objective: This work aims to explore the PubChem library for novel VEGFR-2 kinase inhibitors. 1H-Indazole-containing drug AXITINIB, or AG-013736 (FDA approved), is chosen as a rational molecule for drug design.
Article Synopsis
- The study investigates the role of the central nervous system in sepsis, specifically how the activity of M1/M4 muscarinic acetylcholine receptors (AChRs) affects inflammation in mice following sepsis induced by cecal ligation and puncture (CLP).
- It was found that the activity of certain brain cells (ChAT-expressing neurons) significantly decreased after CLP, leading to increased levels of pro-inflammatory cytokines and changes in immune cell populations.
- Treatment with xanomeline, which stimulates M1AChRs, restored neuronal activity and reduced serum levels of some inflammatory markers, suggesting that enhancing cholinergic activity may help mitigate the inflammatory response in sepsis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!